Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

Andrzej J. Jakubowiak, Ivan Houisse, István Májer, Ágnes Benedict, Marco Campioni, Sumeet Panjabi, Sikander Ailawadhi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: We assessed the economic value of carfilzomib 56 mg/m2 and dexamethasone (Kd56) vs. bortezomib and dexamethasone (Vd) for relapsed/refractory multiple myeloma (R/RMM) using ENDEAVOR trial results. Methods: Cost-effectiveness of Kd56 vs. Vd was assessed using a partitioned survival model by estimating progression-free survival, overall survival, and direct costs over a lifetime horizon. Surveillance Epidemiology and End Results (SEER) survival data were extrapolated after matching registry and ENDEAVOR patients. Utilities were sourced from the literature and mapped from patient-reported quality of life in ENDEAVOR to estimate quality-adjusted life-years (QALYs) from life-years (LYs). Results: The model predicted an average gain of 1.66 LYs and 1.50 QALYs with Kd56 vs. Vd, and lifetime additional costs of $182,699, resulting in an incremental cost-effectiveness ratio (ICER) of $121,828/QALY gained. The ICER was $114,793/QALY in patients with 1 prior treatment; $99,263/QALY in those not transplanted, and <$150,000/QALY up to an 85% discount in bortezomib price. Conclusions: Kd56 is cost-effective for patients with R/RMM at a willingness-to-pay threshold of $150,000/QALY. Trial data in the model may limit generalizability; however, SEER registry data mitigates this challenge. Kd56 provides additional value in key subgroups, and remains cost-effective after steep comparator discounts.

Original languageEnglish (US)
Pages (from-to)1107-1119
Number of pages13
JournalExpert Review of Hematology
Volume10
Issue number12
DOIs
StatePublished - Dec 2 2017

Fingerprint

Quality-Adjusted Life Years
Multiple Myeloma
Dexamethasone
Cost-Benefit Analysis
Costs and Cost Analysis
Survival
Registries
Epidemiology
carfilzomib
Bortezomib
Disease-Free Survival
Economics
Quality of Life

Keywords

  • bortezomib
  • Carfilzomib
  • cost effectiveness
  • ENDEAVOR
  • multiple myeloma
  • progression-free survival
  • refractory
  • relapsed
  • survival

ASJC Scopus subject areas

  • Hematology

Cite this

Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. / Jakubowiak, Andrzej J.; Houisse, Ivan; Májer, István; Benedict, Ágnes; Campioni, Marco; Panjabi, Sumeet; Ailawadhi, Sikander.

In: Expert Review of Hematology, Vol. 10, No. 12, 02.12.2017, p. 1107-1119.

Research output: Contribution to journalArticle

Jakubowiak, Andrzej J. ; Houisse, Ivan ; Májer, István ; Benedict, Ágnes ; Campioni, Marco ; Panjabi, Sumeet ; Ailawadhi, Sikander. / Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. In: Expert Review of Hematology. 2017 ; Vol. 10, No. 12. pp. 1107-1119.
@article{5ce03e896b334f129f0f6388ec210535,
title = "Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States",
abstract = "Background: We assessed the economic value of carfilzomib 56 mg/m2 and dexamethasone (Kd56) vs. bortezomib and dexamethasone (Vd) for relapsed/refractory multiple myeloma (R/RMM) using ENDEAVOR trial results. Methods: Cost-effectiveness of Kd56 vs. Vd was assessed using a partitioned survival model by estimating progression-free survival, overall survival, and direct costs over a lifetime horizon. Surveillance Epidemiology and End Results (SEER) survival data were extrapolated after matching registry and ENDEAVOR patients. Utilities were sourced from the literature and mapped from patient-reported quality of life in ENDEAVOR to estimate quality-adjusted life-years (QALYs) from life-years (LYs). Results: The model predicted an average gain of 1.66 LYs and 1.50 QALYs with Kd56 vs. Vd, and lifetime additional costs of $182,699, resulting in an incremental cost-effectiveness ratio (ICER) of $121,828/QALY gained. The ICER was $114,793/QALY in patients with 1 prior treatment; $99,263/QALY in those not transplanted, and <$150,000/QALY up to an 85{\%} discount in bortezomib price. Conclusions: Kd56 is cost-effective for patients with R/RMM at a willingness-to-pay threshold of $150,000/QALY. Trial data in the model may limit generalizability; however, SEER registry data mitigates this challenge. Kd56 provides additional value in key subgroups, and remains cost-effective after steep comparator discounts.",
keywords = "bortezomib, Carfilzomib, cost effectiveness, ENDEAVOR, multiple myeloma, progression-free survival, refractory, relapsed, survival",
author = "Jakubowiak, {Andrzej J.} and Ivan Houisse and Istv{\'a}n M{\'a}jer and {\'A}gnes Benedict and Marco Campioni and Sumeet Panjabi and Sikander Ailawadhi",
year = "2017",
month = "12",
day = "2",
doi = "10.1080/17474086.2017.1391088",
language = "English (US)",
volume = "10",
pages = "1107--1119",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

AU - Jakubowiak, Andrzej J.

AU - Houisse, Ivan

AU - Májer, István

AU - Benedict, Ágnes

AU - Campioni, Marco

AU - Panjabi, Sumeet

AU - Ailawadhi, Sikander

PY - 2017/12/2

Y1 - 2017/12/2

N2 - Background: We assessed the economic value of carfilzomib 56 mg/m2 and dexamethasone (Kd56) vs. bortezomib and dexamethasone (Vd) for relapsed/refractory multiple myeloma (R/RMM) using ENDEAVOR trial results. Methods: Cost-effectiveness of Kd56 vs. Vd was assessed using a partitioned survival model by estimating progression-free survival, overall survival, and direct costs over a lifetime horizon. Surveillance Epidemiology and End Results (SEER) survival data were extrapolated after matching registry and ENDEAVOR patients. Utilities were sourced from the literature and mapped from patient-reported quality of life in ENDEAVOR to estimate quality-adjusted life-years (QALYs) from life-years (LYs). Results: The model predicted an average gain of 1.66 LYs and 1.50 QALYs with Kd56 vs. Vd, and lifetime additional costs of $182,699, resulting in an incremental cost-effectiveness ratio (ICER) of $121,828/QALY gained. The ICER was $114,793/QALY in patients with 1 prior treatment; $99,263/QALY in those not transplanted, and <$150,000/QALY up to an 85% discount in bortezomib price. Conclusions: Kd56 is cost-effective for patients with R/RMM at a willingness-to-pay threshold of $150,000/QALY. Trial data in the model may limit generalizability; however, SEER registry data mitigates this challenge. Kd56 provides additional value in key subgroups, and remains cost-effective after steep comparator discounts.

AB - Background: We assessed the economic value of carfilzomib 56 mg/m2 and dexamethasone (Kd56) vs. bortezomib and dexamethasone (Vd) for relapsed/refractory multiple myeloma (R/RMM) using ENDEAVOR trial results. Methods: Cost-effectiveness of Kd56 vs. Vd was assessed using a partitioned survival model by estimating progression-free survival, overall survival, and direct costs over a lifetime horizon. Surveillance Epidemiology and End Results (SEER) survival data were extrapolated after matching registry and ENDEAVOR patients. Utilities were sourced from the literature and mapped from patient-reported quality of life in ENDEAVOR to estimate quality-adjusted life-years (QALYs) from life-years (LYs). Results: The model predicted an average gain of 1.66 LYs and 1.50 QALYs with Kd56 vs. Vd, and lifetime additional costs of $182,699, resulting in an incremental cost-effectiveness ratio (ICER) of $121,828/QALY gained. The ICER was $114,793/QALY in patients with 1 prior treatment; $99,263/QALY in those not transplanted, and <$150,000/QALY up to an 85% discount in bortezomib price. Conclusions: Kd56 is cost-effective for patients with R/RMM at a willingness-to-pay threshold of $150,000/QALY. Trial data in the model may limit generalizability; however, SEER registry data mitigates this challenge. Kd56 provides additional value in key subgroups, and remains cost-effective after steep comparator discounts.

KW - bortezomib

KW - Carfilzomib

KW - cost effectiveness

KW - ENDEAVOR

KW - multiple myeloma

KW - progression-free survival

KW - refractory

KW - relapsed

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85036666715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036666715&partnerID=8YFLogxK

U2 - 10.1080/17474086.2017.1391088

DO - 10.1080/17474086.2017.1391088

M3 - Article

C2 - 29027825

AN - SCOPUS:85036666715

VL - 10

SP - 1107

EP - 1119

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 12

ER -